Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Chang
Qing
Q
Division of Applied Molecular Oncology, Ontario Cancer Institute/Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
Chapman
Mark S
MS
Miner
Jeffrey N
JN
Hedley
David W
DW